fi ndings as a randomised controlled trial. 4 Although Heinonen and colleagues' results are in line with our trial data and might support changing vaccination guidelines for young children, cost-eff ectiveness analysis incorporating seasons with vaccine mismatching and statistical uncertainty in effi cacy estimates needs to be done to further convince health politicians and the public. 
Infl uenza vaccination in young children
Santtu Heinonen and colleagues 1 recorded substantial reductions in confi rmed symptomatic episodes of infl uenza in young children who received inactivated infl uenza vaccine with both a non-randomised cohort and case-control design. The casecontrol design was applied to quantify any potential selection bias. However, the main discussion in the discipline currently focuses on potential confounding by risk factors because of diff erential selection for vaccination in non-randomised studies. 2 Average age, for example, diff ered greatly between vaccinated and unvaccinated groups, which will bias the eff ect estimates from the null. The applied stratifi ed analyses for age can eff ectively control such bias. However, parental smoking behaviour and day care attendance were also diff erent between groups, though not statistically signifi cant, and other potential confounders were not reported or measured.
Therefore, results from an earlier randomised controlled trial among children from the Netherlands might be useful. 3 In that trial, 579 children aged 18-72 months were randomly allocated to receive two doses of parenteral inactivated trivalent subunit infl uenza vaccine and placebo, infl uenza vaccine and heptavalent pneumococcal conjugate vaccine, or control recombinant hepatitis B vaccine and placebo. During infl uenza seasons, nose-throat swabs were PCR positive for infl uenza virus in 4% (12 of 271) of children in the fi rst group and in 5% (11 of 243) of children in the second group. In the control group, the incidence was doubled (9%, 25 of 270) and the effi cacy was estimated in both vaccination arms to be around 50% (lower bound 95% CI 3).
These data show that a carefully conducted non-randomised cohort study can produce much the same is poor and often does not provide seroprotection in the fi rst 3 years of life. 2,3 On the basis of this notion, even when the circulating B strain perfectly matches that included in the vaccine, this vaccine is not an ideal means of protecting young children against infl uenza, especially when substantial B-strain circulation is expected.
Because more immunogenic and eff ective vaccines than that used by Heinonen and colleagues will probably be approved for children in the near future, we believe that the investigators' recommendation to use trivalent inactivated infl uenza vaccine in children aged 9 months to 3 years should be less categorical, and that their discussion should have considered data for the new vaccines.
Vesikari and colleagues 3 compared a trivalent inactivated infl uenza vaccine and an MF59-adjuvanted vaccine, and found that MF59 signifi cantly improved immunogenicity against the B vaccine virus and led to greater than 90% seroprotection rates against matched strains in all children irrespective of age. Moreover, a study of the MF59-adjuvanted vaccine in children aged between 6 months and 6 years 4 showed clinical effi cacy rates of 89% against disease caused by vaccine-matched strains and 86% against all circulating strains, which are signifi cantly higher than the 45% and 43% effi cacy of trivalent inactivated infl uenza vaccine reported by Heinonen and colleagues. Live attenuated infl uenza vaccine has an effi cacy of 86% against B strains of the same lineage, 55% against antigenically drifted strains of the same lineage, and 31% against strains of the opposite B lineage that were antigenically unrelated to the vaccine strain. 5 Finally, Heinonen and colleagues recorded no adverse events. Trivalent inactivated infl uenza vaccine is well tolerated, but adverse events occurred in all the other studies and this makes us question whether the assessment was made correctly.
The results of the investigation by Santtu Heinonen and colleagues 1 into the eff ectiveness of a trivalent inactivated infl uenza vaccine in children aged 9 months to 3 years can lead to diff erent conclusions than those drawn by the authors.
The results show that trivalent inactivated infl uenza vaccine is not eff ective against infl uenza B infection, irrespective of age. This fi nding (which was only reported in the discussion) is attributed to the lineage-level mismatch between the circulating B strain and that included in the vaccine, but could have been expected because several studies have shown that the antibody response induced by trivalent inactivated infl uenza vaccine against infl uenza B viruses
